Aduro Biotech Announces Three Grants

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage immunotherapy company, announced today the award of three grants that demonstrate the breadth of applications for the company’s proprietary vaccine platform based on Listeria monocytogenes (Listeria). Aduro has been selected as a subcontractor to the University of New Mexico School of Medicine to continue the company’s award-winning development of vaccines for tularemia as part of a grant from the Defense Threat Reduction Agency (DTRA). Aduro has received a Phase 1 National Institutes of Health (NIH) small business innovation research (SBIR) grant for the development of a therapeutic vaccine for hepatitis B virus (HBV). Aduro has also received a Phase 1 SBIR grant to develop a therapeutic vaccine for melanoma in collaboration with Dr. Nina Bhardwaj, Professor of Medicine, Pathology and Dermatology at the New York University Langone Medical Center.

Back to news